stockrow
Friday 6 November 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
- EPS
- +83.6%
- Free cash flow
- +67.0%
Quarter to June 2026, against a year earlier
0.38
0.08
−17.39%
Follow TPST
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(405.03%) | (203.63%) | (721.00%) | (931.14%) | |
| (141.49%) | (89.91%) | (200.87%) | (237.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(685.44%) | (472.34%) | 13,468.13% | 1,785.27% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(7.52) | (6.46) | (2.41) | (1.36) | |
Free Cash Flow |
(33.39) | (26.82) | (26.38) | (20.73) | |
| Other line items | |||||
Cash ROIC |
(240.95%) | (186.57%) | (1,004.26%) | 6,665.59% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.93 | 1.02 | 0.61 | 0.51 | |
Depreciation/Fixed assets |
0.37 | 0.44 | 0.47 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.52) | (6.46) | (2.41) | (1.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026